Navigation Links
Omeros Announces Positive Clinical Results of Phase 1/Phase 2 Trial of OMS302 for Use During Ophthalmologic Surgery
Date:8/11/2009

SEATTLE, Aug. 11 /PRNewswire/ -- Omeros Corporation today announced results from the Phase 1/Phase 2 clinical trial of OMS302, the Company's ophthalmologic PharmacoSurgery(TM) product candidate. OMS302 is a proprietary combination of an anti-inflammatory agent and an agent that causes pupil dilation (mydriasis), each with well-known safety and pharmacologic profiles.

Omeros' Phase 1/Phase 2 trial enrolled 61 patients undergoing age-related cataract extraction with lens replacement, and was designed to evaluate efficacy and safety of Omeros' product candidate added to a standard surgical irrigation solution. The data from this study showed that patients treated with OMS302 reported less postoperative pain and demonstrated statistically significant improvement in maintenance of mydriasis during the surgical procedure compared to patients treated with vehicle control. There were no serious adverse events and no discontinuations due to adverse events.

This Phase 1/Phase 2 clinical trial was a parallel-group, double-blind, vehicle-controlled study evaluating the effects of OMS302 on dilation of the pupil during cataract surgery and on pain, discomfort and inflammation following the procedure. The trial included three arms of equal size. In the first arm, OMS302 including both the mydriatic and anti-inflammatory agents was added to a standard irrigation solution used in ophthalmologic surgery and delivered directly to the eye during the operation. In the second arm, patients received irrigation solution including only the mydriatic agent, and in the third arm, patients received standard irrigation solution only. For efficacy assessments, patients were monitored for pupil size during surgery and for pain and inflammation for 14 days following surgery.

"We are pleased with the results of this study, which suggest that OMS302 would be useful in helping maintain mydriasis throughout cataract surgery a
'/>"/>

SOURCE Omeros Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Omeros Corporation Files Registration Statement for Proposed Initial Public Offering
2. Omeros Appoints David A. Mann to its Board of Directors
3. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
4. Omeros and BlueCrest Announce $20 Million Debt Facility
5. Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
6. Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinsons Disease Target
7. Omeros Appoints New Vice President of Clinical Development
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... FALLS, N.Y., Jan. 15, 2014   Niagara Thermal ... been selected by Buffalo BioBlower Technologies LLC ("B3") as ... SBIR Phase 2 award from the Army Corps of ... system that kills all biological contaminants and destroys VOCs ...
(Date:1/15/2014)... Cynvenio, a cancer diagnostics company focused ... analysis of tumor cells in the bloodstream, today announced ... decision support application powered by CollabRx, Inc. , ... test, Therapy Finder will provide breast cancer patients and ...
(Date:1/15/2014)... 2014 ­ RedBrick Health , a fast-growing leader ... announces that EmblemHealth , the New ... now providing the RedBrick Compass health assessment, combined with ... of its members. EmblemHealth is among the first health ...
(Date:1/15/2014)... 2014 A study has been launched to ... 1 track could help to tackle the problem of obesity. ... (a GP surgery based in Stowmarket) and academics at University ... Telemetry technology, which is inspired by equipment used to ...
Breaking Biology Technology:Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4
... Feb. 5 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis,Ltd (AXS: PSX; Nasdaq: ... Shareholders on the afternoon of Wednesday 6th February. ... following morning to,review the quarter and answer investor ... (Sydney), on Thursday 7th February,(Wednesday 6thFebruary, at 4.30pm ...
... Blue Cross and Blue Shield of,Texas (BCBSTX) is ... integrated medical-dental program. The program is unique in ... dental data to,create a customized plan aimed to ... specifically help users optimize their overall health by,making ...
... STEWARTVILLE, Minn., Feb. 4 Rochester Medical,Corporation (Nasdaq: ... ending December 31, 2007., The Company reported sales ... the first quarter of last year. It also reported,net ... to a net income,of $31,467,000 or $2.59 per diluted ...
Cached Biology Technology:Blue Cross and Blue Shield of Texas Launches an Integrated Medical-Dental Health Program 2Blue Cross and Blue Shield of Texas Launches an Integrated Medical-Dental Health Program 3Rochester Medical Reports 31% Increase in Branded Sales Resulting in 9% Overall Sales Growth for the First Quarter 2Rochester Medical Reports 31% Increase in Branded Sales Resulting in 9% Overall Sales Growth for the First Quarter 3Rochester Medical Reports 31% Increase in Branded Sales Resulting in 9% Overall Sales Growth for the First Quarter 4Rochester Medical Reports 31% Increase in Branded Sales Resulting in 9% Overall Sales Growth for the First Quarter 5Rochester Medical Reports 31% Increase in Branded Sales Resulting in 9% Overall Sales Growth for the First Quarter 6Rochester Medical Reports 31% Increase in Branded Sales Resulting in 9% Overall Sales Growth for the First Quarter 7
(Date:4/23/2014)... study to date of the family of bacteria ... vaccine strategies and reveals surprising findings about the ... alter public health strategies to control this respiratory ... , Genomic analysis of 343 strains of the ... world collected over the last 100 years illustrates ...
(Date:4/23/2014)... 2014 A biomedical engineer at the University of ... to make blood transfusions safer. His work is supported ... of Health (NIH). , Blood transfusions save millions ... medicine,s absolute necessities. Without them, for instance, routine surgeries ... perfect, however. There,s strong evidence that transfusions of red ...
(Date:4/23/2014)... is leading a 2 million Food Standards Agency (FSA) ... premises and industry workers. , Norovirus outbreaks can ... a batch of frozen strawberries infected 11,000 people in ... understanding of which strains cause infection and which foods ... , Researchers will produce data that will help ...
Breaking Biology News(10 mins):Impact of whooping cough vaccination revealed 2UH biomedical engineer works to make blood transfusions safer 2UH biomedical engineer works to make blood transfusions safer 3
... Major League Baseball pitchers indicates that the height of the ... may lead to potential injuries because of stress on the ... by William Raasch, M.D., associate professor of orthopaedic surgery at ... the head team physician for the Milwaukee Brewers. Major League ...
... a way that had never been observed in any ... Biology, a Cell Press publication. The discoverywhich marks the ... perceive circular polarized light may lend mantis shrimp a ... a new dimension of vision, said Justin Marshall of ...
... Purdue University researchers have identified several soybean varieties that ... Indiana and are resistant to root-knot nematodes, a plant-destroying ... of the state. The researchers verified that resistance ... well the plant will fight off another nematode species, ...
Cached Biology News:Study finds pitching mound height affects throwing motion, injury risk 2Mantis shrimp vision reveals new way that animals can see 2Mantis shrimp vision reveals new way that animals can see 3Soybean varieties viable in southern Indiana, resistant to root-knot nematode 2Soybean varieties viable in southern Indiana, resistant to root-knot nematode 3
Transfection Buffer A & B Set 5 ml each...
Kit contains: Bio-Rad Amplification Reagent, 2x Amplification Diluent, Streptavidin-HRP, Blocking Reagent, and Phosphate Buffered Saline....
Mouse polyclonal antibody to PRDM2 - PR domain containing 2, with ZNF domain...
... 209/ pSer 211 ] affinity isolated antibody ... phosphate buffered saline (without Mg 2+ and ... BSA (IgG and protease free) and 0.05% sodium ... region of mouse Hck that contains tyrosine 207 ...
Biology Products: